{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-000337","form_type":"8-K","ticker":"SNTI","cik":"0001854270","company_name":"Senti Biosciences, Inc.","filed_at":"2025-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.320987+00:00","generated_at":"2026-05-28T11:27:26.147305+00:00","sec_items":["2.03","8.01","3.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Senti Bio secures additional $11.5M from PIPE closing and CIRM grant; cash runway into 2026","bullets":["Closed subsequent PIPE closing with Celadon Partners for additional ~$10M gross proceeds (4,444 Series A shares + warrants for 6,666,000 common shares); total PIPE now $47.6M.","Received $1.5M from CIRM grant; total received $6.4M of $8M grant announced June 2024.","Cash runway guidance extended into 2026; proceeds to fund SENTI-202 development and manufacturing.","Securities sold under Section 4(a)(2)/Rule 506 exemption; registration rights agreement for resale filed."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-000337","json":"https://secwatch.observer/filing/0001140361-25-000337.json","markdown":"https://secwatch.observer/filing/0001140361-25-000337.md","text":"https://secwatch.observer/filing/0001140361-25-000337.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1854270/000114036125000337/0001140361-25-000337-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1854270/000114036125000337/ef20040800_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T11:27:26.147305+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}